PHOENIXVILLE, PA — PleoPharma, Inc. has announced the issuance of two critical U.S. patents that bolster its efforts to treat cannabis withdrawal syndrome (CWS). These patents, U.S. Patent 11,197,846 and U.S. Patent 11,931,334, cover methods and compositions designed to mitigate symptoms of cannabis use disorder, with specific dosing regimens for their developing treatment, PP-01.
The patents represent a significant milestone for PleoPharma, following the success of their Phase 2b clinical trial. “We are pleased to have received the issuance of our second patent following up on the success of our Phase 2b trial. These U.S. patent issuances underscore the scientific achievements of PleoPharma and directly support the commercial value of our programs,” said Ginger Constantine, CEO of PleoPharma. Constantine emphasized the importance of PP-01 in potentially becoming the first approved treatment for the growing number of people affected by CWS.
Cannabis withdrawal symptoms pose a major challenge for individuals trying to reduce or discontinue use. According to recent government data, approximately 19.2 million Americans were diagnosed with cannabis use disorder in 2023, with a significant portion seeking treatment. Despite the increasing need, there are currently no FDA-approved medications for managing cannabis withdrawal.
PleoPharma is also pursuing additional patent applications both in the U.S. and internationally, aiming to expand its intellectual property portfolio. The company recognizes the responsible use of cannabis by many but seeks to provide support for those who develop dependencies, similar to treatments available for alcohol dependence.
As PleoPharma continues to advance PP-01, it hopes to provide a much-needed therapeutic option for individuals struggling with cannabis withdrawal, addressing a significant gap in the current treatment landscape.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.